Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Chinese Journal of cardiovascular Rehabilitation Medicine ; (6): 639-643, 2019.
Artículo en Chino | WPRIM | ID: wpr-790146

RESUMEN

Objective :To observe therapeutic effect of rosuvastatin on patients with coronary heart disease (CHD ) complicated hypertension (EH) and its impact on blood lipids etc .Methods :A total of 112 CHD + EH patients treated in our hospital were randomly and equally divided into routine treatment group and rosuvastatin group .After three‐month treatment ,therapeutic effect was assessed ,levels of blood lipids ,blood pressure and incidence rate of adverse reactions were compared between two groups before and after treatment .Results :Total effective rate of ro‐suvastatin group was significantly higher than that of routine treatment group (92.86% vs.78. 57%, P= 0.031 ). After three‐month treatment ,compared with routine treatment group ,there were significant reductions in serum levels of TC [ (4.18 ± 0.96) mmol/Lvs.(3.21 ± 0. 87) mmol/L] ,TG [ (1. 68 ± 0.54) mmol/Lvs.(1. 31 ± 0. 51) mmol/L] , LDL‐C [ (2. 06 ± 0. 81 ) mmol/Lvs.(1.64 ± 0. 76 ) mmol/L ] , blood pressure [ (140. 77 ± 10.36 )/(82.94 ± 8.87) mmHgvs.(124.23 ± 9.48)/(72.49 ± 7.56 ) mmHg] and arterial plaque score [ (4.36 ± 0.71 ) scores vs .(4. 08 ± 0. 67 ) scores ] , and significant rise in HDL level [ (1.36 ± 0. 41 ) mmol/Lvs.(1. 68 ± 0.49 ) mmol/L] and fore brachial artery endothelium dependent diastolic‐systolic function (FMD) [ (7.36 ± 0. 98)% vs. (8. 59 ± 1. 06)%] in rosuvastatin group , P<0. 05 or <0. 01 .There was no significant difference in incidence rate of adverse reactions between two groups , P= 0.487 .Conclusion : Rosuvastatin possesses significant therapeutic effect on CHD + EH .It can significantly improve levels of blood lipids and blood pressure and arterial function in these patients .

2.
Journal of Applied Clinical Pediatrics ; (24)2006.
Artículo en Chino | WPRIM | ID: wpr-640135

RESUMEN

Objective To explore the clinical significance of monocyte chemoattractant protein-1(MCP-1)in children with Henoch-Schonlein purpura nephritis(HSPN).At the same time compare the association between serum and urine MCP-1,to investigate the impact of the both on them in children with HSPN.Methods Serum and urine MCP-1 were measured by enzyme linked immunosorbent assay in 50 children with Henoch-Schonlein purpura(HSP)(25 cases of them patients with renal injures),and 25 healthy children,the changes of serum and urine MCP-1 were compared;at the same time serum urea nitrogen,creatinine,urinary albumin,urine N-acetyl-D-glucosaminidase(NAG),urine ?2-MG,24 hours urinary levels of protein were investigated in children with HSPN by analyzing the correlation between these indicators and serum and urine MCP-1;urine MCP-1 in HSPN group were measured in recovery period,and were compared with urine MCP-1 in HSP group and HSPN group in acute period.Results 1.The expressions of urine MCP-1 was significantly higher in HSPN group than those in HSP group and healthy controls(P0.05).2.Urine MCP-1 levels were associated with proteinuria in children with HSPN,but serum MCP-1 levels had nothing to do with HSPN.3.There was a close correlation between urine MCP-1 expression and urinary albumin,urine NAG,urine ?2-MG and 24 hours urinary levels of protein,but the expression of urine MCP-1 levels were not correlated with the serum urea nitrogen and creatinine.4.There was statistical significance in urine MCP-1 in acute and recovery periods with HSPN group(P

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA